Home » Stocks » VYNE Therapeutics

VYNE Therapeutics, Inc. (VYNE)

Stock Price: $1.86 USD -0.06 (-3.13%)
Updated Oct 23, 2020 3:02 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 311.91M
Revenue (ttm) 13.44M
Net Income (ttm) -246.03M
Shares Out 167.69M
EPS (ttm) -3.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $1.86
Previous Close $1.92
Change ($) -0.06
Change (%) -3.13%
Day's Open 1.92
Day's Range 1.85 - 1.92
Day's Volume 747,686
52-Week Range 1.00 - 7.48

More Stats

Market Cap 311.91M
Enterprise Value 246.96M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 167.69M
Float 159.26M
EPS (basic) -3.75
EPS (diluted) -3.75
FCF / Share -0.87
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.63M
Short Ratio 3.13
Short % of Float 4.79%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 23.21
PB Ratio 4.50
Revenue 13.44M
Operating Income -246.42M
Net Income -246.03M
Free Cash Flow -120.98M
Net Cash 64.94M
Net Cash / Share 0.39
Gross Margin 3.26%
Operating Margin -1,833.77%
Profit Margin -1,830.80%
FCF Margin -900.25%
ROA -68.11%
ROE -407.33%
ROIC -453.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.07*
(280.11% upside)
Low
3.00
Current: $1.86
High
15.00
Target: 7.07
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-10.644.580.67-
Revenue Growth-132.21%579.82%--
Gross Profit-10.644.580.67-
Operating Income-76.24-54.54-29.59-14.33-4.61
Net Income-73.70-51.45-29.08-14.07-4.61
Shares Outstanding23.8221.675.114.994.74
Earnings Per Share-3.09-2.37-5.69-2.82-0.97
Operating Cash Flow-65.10-52.73-28.22-2.27-4.18
Capital Expenditures-0.01-0.14-0.03-0.03-
Free Cash Flow-65.11-52.87-28.25-2.30-4.18
Cash & Equivalents73.3713659.5030.9143.81
Total Debt34.47----
Net Cash / Debt38.9013659.5030.9143.81
Assets81.1614066.8742.0543.89
Liabilities63.589.5514.5712.490.84
Book Value17.58130-57.03-29.44-15.95
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name VYNE Therapeutics, Inc.
Country United States
Employees 40
CEO David Domzalski

Stock Information

Ticker Symbol VYNE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VYNE
IPO Date January 25, 2018

Description

VYNE Therapeutics, a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is headquartered in Bridgewater, New Jersey.